PRISM Stock Indexes
Current Value
% Change (Daily)
% Change (Inception)
Top % Gainers
% Change
Top % Losers
% Change
Emerging Semiconductors $131.16 0.55% 31.16% NVEC   2.96% GSIT   -3.77%
Emerging Pet Care $98.79 -0.65% -1.21% PETZ   2.17% CHWY   -3.01%
Aerospace and Defense $124.17 0.02% 24.17% TAKOF   4.76% SRFM   -11.96%
AI Datacenter and Infrastructure $313.99 2.22% 213.99% HUT   8.83% AISP   -3.48%
Beauty and Wellness $76.42 -0.40% -23.58% FIGS   3.13% BODI   -5.77%
Biotech $162.18 -1.20% 62.18% TRDA   5.92% EQ   -12.81%
Emerging Cannabis $108.95 -0.53% 8.95% AAWH   6.81% GTBIF   -3.20%
Emerging Comms and Media $181.48 1.38% 81.48% VERI   18.15% CREX   -2.41%
Emerging Consumer Products $155.65 1.40% 55.65% TBCH   8.19% BRLT   -5.33%
Emerging Crypto Mining $228.58 3.47% 128.58% CAN   9.04% IREN   0.44%
Cybersecurity $137.43 -1.41% 37.43% AUID   12.51% HUBC   -18.21%
Emerging EV $110.57 0.84% 10.57% BEEM   3.62% LAC   -3.64%
Emerging Fintech $128.06 -0.27% 28.06% VYX   5.95% PMTS   -16.48%
Emerging Global Health $171.09 -0.63% 71.09% LGVN   10.39% SPRY   -5.93%
Emerging Healthcare $122.21 0.04% 22.21% DXR   5.81% OMDA   -8.56%
Emerging NextGen Tech & AI $155.40 1.59% 55.40% QTEX   8.75% KSCP   -3.90%
Emerging New Energy $134.25 -1.35% 34.25% BW   10.74% OKLO   -9.18%
Emerging MedTech Index $144.10 0.00% 44.10% TELA   7.17% BIAF   -15.34%
Emerging Mental Health $150.32 1.35% 50.32% RLMD   11.06% CING   -2.90%
Emerging Oil & Gas $138.85 -0.49% 38.85% IMPP   3.30% TPET   -6.93%
Emerging Pharmaceuticals $326.20 -0.52% 226.20% ATNM   6.87% CADL   -6.93%
Emerging Precious Metals $261.70 -0.56% 161.70% GROY   3.96% ASM   -8.85%
Emerging Psychedelics $549.11 0.79% 449.11% PBM   8.65% ENVB   -2.74%
Emerging Space $353.69 0.40% 253.69% CMTL   3.42% RDW   -2.30%
Emerging Sports $124.45 0.01% 24.45% MSGM   7.34% GAIA   -7.53%
Emerging Weight Loss $148.18 -0.52% 48.18% RYTM   2.46% GPCR   -2.25%
Emerging Women’s Health $131.26 0.46% 31.26% NVCT   6.67% PDSB   -6.47%
View All

PRISM View

UBS Downgrades NuScale Power to Sell, Sending SMR Shares Down 11% as Analysts Split the Nuclear Trade

UBS downgraded NuScale Power Corporation (NYSE: SMR) to Sell from Neutral on Friday and slashed its price target to $6, driving shares down roughly 11% to about $9.09 in morning trading. The call marks the second analyst action to hit the s...

Wealthfront Crosses $100 Billion in Platform Assets While Rate Cuts Erode the Business That Built It

Wealthfront Corporation (NASDAQ: WLTH), a tech-driven financial platform serving digital-native savers and investors, reported fiscal second quarter 2027 results on September 9, 2026 for the quarter ended July 31, 2026. Total platform asset...

Draganfly Wins a Five-Year Canadian Armed Forces Contract, Capping Three Defense Announcements in Four Days

Draganfly Inc. (NASDAQ: DPRO), a developer of drone solutions and systems, announced on September 11, 2026 that the Government of Canada awarded it a five-year contract to supply Low-Cost Tactical Intelligence, Surveillance and Reconnaissan...

Tenable Retains No. 1 Market Share in Device Vulnerability Management for Eighth Year

Key Points Tenable Holdings ranked first in worldwide device vulnerability and exposure management market share for the eighth consecutive year, according to IDC. IDC reported that Tenable held 24.6% of the global market and led its...

Oracle’s AI Data Center Bet Delivers: Cloud Infrastructure Revenue Surges 121%

Oracle Corporation (NYSE: ORCL) delivered a fiscal first-quarter beat that landed squarely on the metric Wall Street cares about most. The company's cloud infrastructure business more than doubled year over year, signaling that its aggressi...

Archer and BETA Bring ACES Charging to Texas, Turning a Consortium Announcement Into a State Partnership

Archer Aviation Inc. (NYSE: ACHR), an aerospace company developing electric vertical takeoff and landing aircraft, announced on September 10, 2026 that America’s Consortium for Electric Skyways will bring its interoperable charging networ...

Cannabis Strategic Ventures Targets Mobile Ad-Tech Pivot With Proposed Adport Acquisition

Key Points Cannabis Strategic Ventures signed a non-binding letter of intent to acquire Adport’s operating assets and intellectual property. Adport develops mobile, battery-powered digital advertising screens for delivery riders a...

Babcock & Wilcox Begins Work on a $130 Million Coal Plant Emissions Project as Litigation Over an Earlier Contract Continues

Babcock & Wilcox Enterprises, Inc. (NYSE: BW), a provider of energy and environmental products and services for power and industrial markets, announced on September 10, 2026 that it has received a limited notice to proceed on an approxi...

SKYX Signs Merger Agreement With Deako to Combine Plug-and-Play Smart Home Platforms

SKYX Platforms Corp. (NASDAQ: SKYX) has signed a merger agreement with Deako Inc., a Silicon Valley-backed smart-home technology company. The proposed combination brings together SKYX’s ceiling-based plug-and-play electrical platform and ...

PRISM Mid-Day Movers: New Energy and Oil & Gas are Today’s Leaders.

Sky Quarry Inc. (NASDAQ: SKYQ) jumped 23.51% to $3.2977 in Thursday trading, adding $0.6277 from its prior close of $2.67. The stock opened at $3.17 and traded between $2.98 and $3.80, while volume surged to 24.53 million shares—well abov...

Galaxy Secures Conditional ERCOT Classifications for 4.2 GW, But Only 1.6 GW Cleared as Base Load

Galaxy Digital Inc. (NASDAQ: GLXY), a digital assets and data center infrastructure company, announced on September 8, 2026 that five of its Texas data center projects received conditional classifications under the ERCOT Batch Zero large lo...

Rocket Lab Releases a Germanium-Free Space Solar Cell, Engineering Around a Chinese Supply Chokepoint

Rocket Lab Corporation (NASDAQ: RKLB), a global leader in launch services and space systems, announced the production release of IMM Apex on September 8, 2026, a next-generation Inverted Metamorphic solar cell built without the germanium su...

Bio View

Cardiol Therapeutics Files US$150 Million Shelf Prospectus Ahead of CardiolRx Milestones

Key Points Cardiol Therapeutics filed a preliminary US$150 million base shelf prospectus in Canada and a related Form F-10 registration statement with the U.S. Securities and Exchange Commission. If finalized, the shelf could allow ...

NRx’s HOPE Therapeutics Prepares First Robotic TMS Deployment in Florida

Key Points NRx Pharmaceuticals’ HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS, system in Florida clinics. HOPE said it will become the first int...

Rhythm Highlights Setmelanotide Benefits in Pediatric Hypothalamic Obesity Studies

Key Points Rhythm Pharmaceuticals presented real-world and Phase 3 data on setmelanotide in children with acquired hypothalamic obesity at ESPE 2026. A French early-access analysis of 30 patients found reductions in BMI and hunger s...

Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer

Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep dosing period, the combinatio...

bioAffinity Clears Nasdaq Hurdle, Securing Continued Trading for BIAF and BIAFW

Key Points bioAffinity Technologies regained compliance with Nasdaq’s minimum bid-price and warrants listing requirements. Nasdaq cancelled the company’s previously scheduled hearing before the Nasdaq Hearings Panel. bioAffin...

Actuate Reports Preclinical Synergy for Elraglusib With RAS Inhibitors in Pancreatic Cancer

Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested elraglusib with zoldonrasib, a KRA...

Kazia Doses First Patient in Phase 2 Paxalisib Trial for Recurrent AT/RT Brain Cancer

Key Points Kazia Therapeutics dosed the first patient in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent or progressive AT/RT. The study will enroll patients ages 1 to 39 with atypical teratoid/rhabdoid tumor, a...

Opus Gene Therapy Shows Early Vision Improvements in BEST1 Retinal Disease Trial

Key Points Opus Genetics reported positive early data from five patients treated with OPGx-BEST1 in a Phase 1/2 study of inherited BEST1-related retinal diseases. All five patients showed clinically meaningful improvement in at leas...

Serina Moves SER-252 Into Second Dose Cohort for Advanced Parkinson’s Disease

Key Points Serina Therapeutics advanced its SER-252 Phase 1b study to Cohort 2 after an independent safety committee reviewed blinded data from the first patient group. The first cohort included eight people with Parkinson’s disea...

PDS Biotech Raises Up to $22.55 Million to Advance Cancer Drug Programs

Key Points PDS Biotechnology announced a PIPE financing of up to $22.55 million led by Nant Capital. The company expects an initial $11.55 million closing around September 11, 2026, subject to closing conditions. A further $11 mi...

Compass Pathways Launches TRD Education Campaign at Psych Congress 2026

Key Points Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans. The campaign focuses on the neurobiology of treatment-resistant depression a...

BrainsWay Pilot Study Links Deep TMS to Depression Improvement in Early Alzheimer’s Patients

Key Points BrainsWay reported results from a 12-patient pilot study of Deep TMS in people with major depressive disorder and early-stage Alzheimer’s disease. After 36 treatment sessions, 83.3% of participants met the study’s def...

Q&A Corner

Building Regulated Infrastructure Across Traditional and Digital Asset Markets

This interview contains forward-looking statements, including statements regarding the proposed acquisitions, expected closing timelines, anticipated financial contributions and accretion, and planned regulatory filings. These statements ar...

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup